G1359A polymorphism in the cannabinoid receptor-1 gene is associated with coronary artery disease in the Chinese Han population

Clinical Laboratory

Volumn 57, Issue 9-10, 2011, Pages 689-693

  Liu, Rui ^a   Zhang, Yanjun ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cannabinoid receptor 1; Coronary artery disease; Polymorphism

Indexed keywords

CANNABINOID 1 RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHINA; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; RISK FACTORS;

EID: 80054790320     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Visvikis-Siest S, Marteau JB. Genetic variants predisposing to cardiovascular disease. Curr Opin Lipidol 2006;17:139-51.
2. Jbilo O, Ravinet-Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005;19:1567-9. (Pubitemid 41279033)
3. 2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006;39:155-62.
4. Viveros MP, de Fonseca FR, Bermudez-Silva FJ, McPartland JM. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocr Metab Immune Disord Drug Targets 2008;8:220-30.
5. Sugamura K, Sugiyama S, Nozaki T, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009;119:28-36.
6. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008;299:1547-60. (Pubitemid 351482794)
7. González Sagrado M, Aller R, Izaola O, Conde R. Influence of G1359A polymorphism of the cannabinoid receptor gene on anthropometric parameters and insulin resistance in women with obesity. Metabolism 2010.
8. Baye TM, Zhang Y, Smith E, et al. Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. Pharmacogenomics 2008;9:1647-56.
9. Luis DA, González Sagrado M, Aller R, et al. G1359A polymerphism of the cannabinoid receptor gene (CNR1) on anthropometric parameters and cardiovascular risk factors in patients with morbid obesity. Nutr Hosp 2009;24:688-92.
10. Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007;120:S12-8.
11. Jaeger JP, Mattevi VS, Callegari-Jacques SM, Hutz MH. Cannabinoid type-1 receptor gene polymorphisms are associated with central obesity in a Southern Brazilian population. Dis Markers 2008;25:67-74.
12. Nogueiras R, Diaz-Arteaga A, Lockie SH, et al. The endocannabinoid system: role in glucose and energy metabolism. Pharmacol Res 2009;60:93-8.
13. Scheen AJ, Van Gaal LF. Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes. Rev Med Liege 2007;62:81-5. (Pubitemid 351448356)
14. Gazzerro P, Caruso MG, Notarnicola M, et al. Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes (Lond) 2007;31:908-12. (Pubitemid 46842680)
15. Frost M, Nielsen T, Wraae K, et al. Polymorphisms in the endocannabinoid-receptor 1 in relation to fat mass distribution. Eur J Endocrinol 2010;163:407-12.
16. Arsenault BJ, Rana JS, Lemieux I, et al. Physical inactivity, abdominal obesity and risk of coronary heart disease in apparently healthy men and women. Int J Obes (Lond) 2010;34:340-7.
17. Freedman DS, Khan LK, Dietz WH, Srinivasan SR, Berenson GS. Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart Study. Pediatrics 2001;108:712-8. (Pubitemid 32786603)
18. Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008;31:S229-40.
19. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002;25:1177-84. (Pubitemid 41071169)
20. Després JP, Ross R, Boka G, Alméras N, Lemieux I; ADAGIO-Lipids Investigators. Effect of rimonabant on the high-triglyceride/low- HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009;29:416-23.
21. Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol 2001;87:2B-7B. (Pubitemid 32274237)